Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

View More View Less
  • 1 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;
  • 2 Vanderbilt-Ingram Cancer Center;
  • 3 Mayo Clinic Cancer Center;
  • 4 University of Wisconsin Carbone Cancer Center;
  • 5 University of Colorado Cancer Center;
  • 6 Duke Cancer Institute;
  • 7 UCSF Helen Diller Family Comprehensive Cancer Center;
  • 8 City of Hope National Medical Center;
  • 9 Patient Advocate;
  • 10 Massachusetts General Hospital Cancer Center;
  • 11 The University of Texas MD Anderson Cancer Center;
  • 12 Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;
  • 13 Memorial Sloan Kettering Cancer Center;
  • 14 Moffitt Cancer Center;
  • 15 Fox Chase Cancer Center;
  • 16 Stanford Cancer Institute;
  • 17 UCLA Jonsson Comprehensive Cancer Center;
  • 18 O'Neal Comprehensive Cancer Center at UAB;
  • 19 Dana-Farber/Brigham and Women’s Cancer Center;
  • 20 Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;
  • 21 Abramson Cancer Center at the University of Pennsylvania;
  • 22 Robert H. Lurie Comprehensive Cancer Center of Northwestern University;
  • 23 UC San Diego Moores Cancer Center;
  • 24 University of Michigan Rogel Cancer Center;
  • 25 UT Southwestern Simmons Comprehensive Cancer Center;
  • 26 The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;
  • 27 Yale Cancer Center/Smilow Cancer Hospital;
  • 28 Fred & Pamela Buffett Cancer Center;
  • 29 Huntsman Cancer Institute at the University of Utah;
  • 30 Roswell Park Comprehensive Cancer Center; and
  • 31 National Comprehensive Cancer Network
Restricted access

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country’s fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating in the ovary, fallopian tube, or peritoneum, as these are all managed in a similar manner. Most of the recommendations are based on data from patients with the most common subtypes─high-grade serous and grade 2/3 endometrioid. The NCCN Guidelines also include recommendations specifically for patients with less common ovarian cancers, which in the guidelines include the following: carcinosarcoma, clear cell carcinoma, mucinous carcinoma, low-grade serous, grade 1 endometrioid, borderline epithelial, malignant sex cord-stromal, and malignant germ cell tumors. This manuscript focuses on certain aspects of primary treatment, including primary surgery, adjuvant therapy, and maintenance therapy options (including PARP inhibitors) after completion of first-line chemotherapy.

Individual Disclosures for the NCCN Ovarian Cancer Panel

T15

Supplementary Materials

    • Supplemental Materials (PDF 493 KB)
  • 1.

    Erickson BK, Martin JY, Shah MM, . Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center. Gynecol Oncol 2014;133:142146.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Bristow RE, Chang J, Ziogas A, . Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival. J Am Coll Surg 2015;220:940950.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Ledermann JA, Raja FA, Fotopoulou C, . Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi24vi32.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Bristow RE, Chang J, Ziogas A, . Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol 2013;121:12261234.

  • 5.

    Fleming GF, Seidman J, Lengyel E, . Epithelial ovarian cancer. In: Chi D, Berchuck A, Dizon DS, Yashar CM, eds. Principles and Practice of Gynecologic Oncology, 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2017:611–705.

    • Export Citation
  • 6.

    Wright AA, Bohlke K, Armstrong DK, . Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol 2016;143:315.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    van Meurs HS, Tajik P, Hof MH, . Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. Eur J Cancer 2013;49:31913201.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Tew WP, Lacchetti C, Ellis A, . PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol 2020;38:34683493.

  • 9.

    Ferrell BR, Temel JS, Temin S, . Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2017;35:96112.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Rimel BJ, Burke WM, Higgins RV, . Improving quality and decreasing cost in gynecologic oncology care. Society of gynecologic oncology recommendations for clinical practice. Gynecol Oncol 2015;137:280284.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Hay CM, Lefkowits C, Crowley-Matoka M, . Strategies for introducing outpatient specialty palliative care in gynecologic oncology. J Oncol Pract 2017;13:e712e720.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Giede KC, Kieser K, Dodge J, . Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 2005;99:447461.

  • 13.

    Earle CC, Schrag D, Neville BA, . Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006;98:172180.

  • 14.

    du Bois A, Quinn M, Thigpen T, . 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16 Suppl 8:viii7-viii12.

  • 15.

    Cliby WA, Powell MA, Al-Hammadi N, . Ovarian cancer in the United States: contemporary patterns of care associated with improved survival. Gynecol Oncol 2015;136:1117.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Schorge JO, Eisenhauer EE, Chi DS. Current surgical management of ovarian cancer. Hematol Oncol Clin North Am 2012;26:93109.

  • 17.

    Whitney CW, Spirtos N. Gynecologic Oncology Group surgical procedures manual. Gynecologic Oncology Group, Philadelphia. 2009.

  • 18.

    Ulrich U, Paulus W, Schneider A, . Laparoscopic surgery for complex ovarian masses. J Am Assoc Gynecol Laparosc 2000;7:373380.

  • 19.

    Chi DS, Abu-Rustum NR, Sonoda Y, . The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol 2005;192:16141619.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Park JY, Kim DY, Suh DS, . Comparison of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer. Ann Surg Oncol 2008;15:20122019.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Park JY, Bae J, Lim MC, . Laparoscopic and laparotomic staging in stage I epithelial ovarian cancer: a comparison of feasibility and safety. Int J Gynecol Cancer 2008;18:12021209.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22.

    Medeiros LR, Rosa DD, Bozzetti MC, . Laparoscopy versus laparotomy for FIGO Stage I ovarian cancer. Cochrane Database Syst Rev 2008; (4):CD005344.

    • Search Google Scholar
    • Export Citation
  • 23.

    Colomer AT, Jiménez AM, Bover Barceló MI. Laparoscopic treatment and staging of early ovarian cancer. J Minim Invasive Gynecol 2008;15:414419.

  • 24.

    Ghezzi F, Cromi A, Bergamini V, . Should adnexal mass size influence surgical approach? A series of 186 laparoscopically managed large adnexal masses. BJOG 2008;115:10201027.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Nezhat FR, DeNoble SM, Liu CS, . The safety and efficacy of laparoscopic surgical staging and debulking of apparent advanced stage ovarian, fallopian tube, and primary peritoneal cancers. JSLS 2010;14:155168.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Covens AL, Dodge JE, Lacchetti C, . Surgical management of a suspicious adnexal mass: a systematic review. Gynecol Oncol 2012;126:149156.

  • 27.

    Brockbank EC, Harry V, Kolomainen D, . Laparoscopic staging for apparent early stage ovarian or fallopian tube cancer. First case series from a UK cancer centre and systematic literature review. Eur J Surg Oncol 2013;39:912917.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Park HJ, Kim DW, Yim GW, . Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis. Am J Obstet Gynecol 2013;209:e5158.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29.

    Gouy S, Belghiti J, Uzan C, . Accuracy and reproducibility of the peritoneal cancer index in advanced ovarian cancer during laparoscopy and laparotomy. Int J Gynecol Cancer 2013;23:16991703.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Fanning J, Kesterson J, Benton A, . Laparoscopy-assisted supracervical hysterectomy for ovarian cancer: cervical recurrence. JSLS 2014;18:18.

  • 31.

    Favero G, Macerox N, Pfiffer T, . Oncologic concerns regarding laparoscopic cytoreductive surgery in patients with advanced ovarian cancer submitted to neoadjuvant chemotherapy. Oncology 2015;89:159166.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Lu Q, Qu H, Liu C, . Comparison of laparoscopy and laparotomy in surgical staging of apparent early ovarian cancer: 13-year experience. Medicine (Baltimore) 2016;95:e3655.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Li T, Tan J, Cohen P. A novel surgical technique for the large ovarian cystic mass - combined mini-laparotomy and laparoscopy. Eur J Gynaecol Oncol 2016;37:766770.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Gueli Alletti S, Petrillo M, Vizzielli G, . Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study. Gynecol Oncol 2016;143:516520.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35.

    Gueli Alletti S, Bottoni C, Fanfani F, . Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study. Am J Obstet Gynecol 2016;214:e501e506.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36.

    Gallotta V, Ghezzi F, Vizza E, . Laparoscopic management of ovarian cancer patients with localized carcinomatosis and lymph node metastases: results of a retrospective multi-institutional series. J Minim Invasive Gynecol 2016;23:590596.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Tozzi R, Gubbala K, Majd HS, . Interval laparoscopic en-bloc resection of the pelvis (L-EnBRP) in patients with stage IIIC-IV ovarian cancer: description of the technique and surgical outcomes. Gynecol Oncol 2016;142:477483.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Bogani G, Borghi C, Ditto A, . Impact of surgical route in influencing the risk of lymphatic complications after ovarian cancer staging. J Minim Invasive Gynecol 2017;24:739746.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Bogani G, Borghi C, Leone Roberti Maggiore U, . Minimally invasive surgical staging in early-stage ovarian carcinoma: a systematic review and meta-analysis. J Minim Invasive Gynecol 2017;24:552562.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Melamed A, Keating NL, Clemmer JT, . Laparoscopic staging for apparent stage I epithelial ovarian cancer. Am J Obstet Gynecol 2017;216:e50e51–.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 41.

    Gallotta V, Cicero C, Conte C, . Robotic versus laparoscopic staging for early ovarian cancer: a case-matched control study. J Minim Invasive Gynecol 2017;24:293298.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Ditto A, Bogani G, Martinelli F, . Minimally invasive surgical staging for ovarian carcinoma: a propensity-matched comparison with traditional open surgery. J Minim Invasive Gynecol 2017;24:98102.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Radosa JC, Radosa MP, Schweitzer PA, . Report of the survey on current opinions and practice of German Society for Gynecologic Endoscopy (AGE) members regarding the laparoscopic treatment of ovarian malignancies. Arch Gynecol Obstet 2018;297:12551264.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Ceccaroni M, Roviglione G, Bruni F, . Laparoscopy for primary cytoreduction with multivisceral resections in advanced ovarian cancer: prospective validation. “The times they are a-changin”? Surg Endosc 2018;32:20262037.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Jochum F, Vermel M, Faller E, . Three and five-year mortality in ovarian cancer after minimally invasive compared with open surgery: a systematic review and meta-analysis. J Clin Med 2020;9:9.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 46.

    Gueli Alletti S, Capozzi VA, Rosati A, . Laparoscopy vs. laparotomy for advanced ovarian cancer: a systematic review of the literature. Minerva Med 2019;110:341357.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 47.

    Cardenas-Goicoechea J, Wang Y, McGorray S, . Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis. J Robot Surg 2019;13:2333.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Behbehani S, Suarez-Salvador E, Buras M, . Mortality rates in laparoscopic and robotic gynecologic oncology surgery: a systemic review and meta-analysis. J Minim Invasive Gynecol 2019;26:12531267.e4.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Lécuru F, Desfeux P, Camatte S, . Impact of initial surgical access on staging and survival of patients with stage I ovarian cancer. Int J Gynecol Cancer 2006;16:8794.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 50.

    Bogani G, Cromi A, Serati M, . Laparoscopic and open abdominal staging for early-stage ovarian cancer: our experience, systematic review, and meta-analysis of comparative studies. Int J Gynecol Cancer 2014;24:12411249.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Gallotta V, Fagotti A, Fanfani F, . Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience. Surg Endosc 2014;28:18081815.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Minig L, Saadi J, Patrono MG, . Laparoscopic surgical staging in women with early stage epithelial ovarian cancer performed by recently certified gynecologic oncologists. Eur J Obstet Gynecol Reprod Biol 2016;201:94100.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Xiong W, Cao LL, Jiang LP, . [Clinical comparative analysis of comprehensive laparoscopic and laparotomic staging of early-stage epithelial ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi 2017;52:103109.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Liu CS, Nagarsheth NP, Nezhat FR. Laparoscopy and ovarian cancer: a paradigm change in the management of ovarian cancer? J Minim Invasive Gynecol 2009;16:250262.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Mori KM, Neubauer NL. Minimally invasive surgery in gynecologic oncology. ISRN Obstet Gynecol 2013;2013:312982.

  • 56.

    Dodge JE, Covens AL, Lacchetti C, . Management of a suspicious adnexal mass: a clinical practice guideline. Curr Oncol 2012;19:e244e257.

  • 57.

    Fagotti A, Ferrandina G, Fanfani F, . Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol 2008;199:e641646.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 58.

    Fagotti A, Fanfani F, Vizzielli G, . Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery? Gynecol Oncol 2010;116:7277.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Rutten MJ, Gaarenstroom KN, Van Gorp T, . Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study. BMC Cancer 2012;12:31.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Fagotti A, Vizzielli G, Fanfani F, . Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. Gynecol Oncol 2013;131:341346.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 61.

    Fagotti A, Vizzielli G, De Iaco P, . A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol 2013;209:462.e1e11.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 62.

    Vizzielli G, Costantini B, Tortorella L, . Influence of intraperitoneal dissemination assessed by laparoscopy on prognosis of advanced ovarian cancer: an exploratory analysis of a single-institution experience. Ann Surg Oncol 2014;21:39703977.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Rutten MJ, van Meurs HS, van de Vrie R, . Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: a randomized controlled trial. J Clin Oncol 2017;35:613621.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Tomar TS, Nair RP, Sambasivan S, . Role of laparoscopy in predicting surgical outcomes in patients undergoing interval cytoreduction surgery for advanced ovarian carcinoma: A prospective validation study. Indian J Cancer 2017;54:550555.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    van de Vrie R, van Meurs HS, Rutten MJ, . Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer. Gynecol Oncol 2017;146:449456.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 66.

    Fleming ND, Nick AM, Coleman RL, . Laparoscopic surgical algorithm to triage the timing of tumor reductive surgery in advanced ovarian cancer. Obstet Gynecol 2018;132:545554.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Greggi S, Falcone F, Scaffa C, . Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey. Int J Gynecol Cancer 2020;30:819824.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Fagotti A, Ferrandina G, Vizzielli G, . Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. Eur J Cancer 2016;59:2233.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Vergote I, Tropé CG, Amant F, . Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943953.

  • 70.

    Kehoe S, Hook J, Nankivell M, . Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015;386:249257.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Onda T, Satoh T, Saito T, . Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer 2016;64:2231.

    • Search Google Scholar
    • Export Citation
  • 72.

    Liu EL, Mi RR, Wang DH, . Application of combined intraperitoneal and intravenous neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and massive ascites. Eur J Gynaecol Oncol 2017;38:209213.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med 2018;378:400401.

  • 74.

    Oktay K, Harvey BE, Partridge AH, . Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2018;36:19942001.

  • 75.

    Schüring AN, Fehm T, Behringer K, . Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation. Arch Gynecol Obstet 2018;297:241255.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Liu D, Cai J, Gao A, . Fertility sparing surgery vs radical surgery for epithelial ovarian cancer: a meta-analysis of overall survival and disease-free survival. BMC Cancer 2020;20:320.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Nasioudis D, Mulugeta-Gordon L, McMinn E, . Fertility sparing surgery for patients with FIGO stage I clear cell ovarian carcinoma: a database analysis and systematic review of the literature. Int J Gynecol Cancer 2020;30:13721377.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 78.

    Yoshihara M, Kajiyama H, Tamauchi S, . Prognostic factors and effects of fertility-sparing surgery in women of reproductive age with ovarian clear-cell carcinoma: a propensity score analysis. J Gynecol Oncol 2019;30:e102.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Kajiyama H, Yoshihara M, Tamauchi S, . Fertility-Sparing surgery for young women with ovarian endometrioid carcinoma: a multicenteric comparative study using inverse probability of treatment weighting. Eur J Obstet Gynecol Reprod Biol X 2019;4:100071.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Hedbäck NE, Karlsen MA, Høgdall CK, . Survival of selected patients with ovarian cancer treated with fertility-sparing surgery. Reprod Biomed Online 2018;37:7176.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Nasioudis D, Chapman-Davis E, Frey MK, . Could fertility-sparing surgery be considered for women with early stage ovarian clear cell carcinoma? J Gynecol Oncol 2017;28:e71.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Melamed A, Rizzo AE, Nitecki R, . All-cause mortality after fertility-sparing surgery for stage I epithelial ovarian cancer. Obstet Gynecol 2017;130:7179.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 83.

    Jiang X, Yang J, Yu M, . Oncofertility in patients with stage I epithelial ovarian cancer: fertility-sparing surgery in young women of reproductive age. World J Surg Oncol 2017;15:154.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 84.

    Fruscio R, Ceppi L, Corso S, . Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer. Br J Cancer 2016;115:641648.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Crafton SM, Cohn DE, Llamocca EN, . Fertility-sparing surgery and survival among reproductive-age women with epithelial ovarian cancer in 2 cancer registries. Cancer 2020;126:12171224.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Park JY, Kim DY, Kim JH, . Surgical management of borderline ovarian tumors: the role of fertility-sparing surgery. Gynecol Oncol 2009;113:7582.

  • 87.

    Song T, Choi CH, Park HS, . Fertility-sparing surgery for borderline ovarian tumors: oncologic safety and reproductive outcomes. Int J Gynecol Cancer 2011;21:640646.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Sun H, Chen X, Zhu T, . Age-dependent difference in impact of fertility preserving surgery on disease-specific survival in women with stage I borderline ovarian tumors. J Ovarian Res 2018;11:54.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 89.

    Johansen G, Dahm-Kähler P, Staf C, . Reproductive and obstetrical outcomes with the overall survival of fertile-age women treated with fertility-sparing surgery for borderline ovarian tumors in Sweden: a prospective nationwide population-based study. Fertil Steril 2021;115:157163..

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Zhang M, Cheung MK, Shin JY, . Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women. Gynecol Oncol 2007;104:396400.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 91.

    Lee IH, Choi CH, Hong DG, . Clinicopathologic characteristics of granulosa cell tumors of the ovary: a multicenter retrospective study. J Gynecol Oncol 2011;22:188195.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Mangili G, Ottolina J, Gadducci A, . Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary. Br J Cancer 2013;109:2934.

  • 93.

    Neeyalavira V, Suprasert P. Outcomes of malignant ovarian germ-cell tumors treated in Chiang Mai University Hospital over a nine year period. Asian Pac J Cancer Prev 2014;15:49094913.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 94.

    Shim SH, Lee SJ, Kim DY, . A Long-term follow-up study of 91 cases with ovarian granulosa cell tumors. Anticancer Res 2014;34:10011010.

  • 95.

    Nasioudis D, Chapman-Davis E, Frey MK, . Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base. Gynecol Oncol 2017;147:296301.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Turkmen O, Karalok A, Basaran D, . Fertility-sparing surgery should be the standard treatment in patients with malignant ovarian germ cell tumors. J Adolesc Young Adult Oncol 2017;6:270276.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Bergamini A, Ferrandina G, Candiani M, . Laparoscopic surgery in the treatment of stage I adult granulosa cells tumors of the ovary: Results from the MITO-9 study. Eur J Surg Oncol 2018;44:766770.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 98.

    Bergamini A, Cormio G, Ferrandina G, . Conservative surgery in stage I adult type granulosa cells tumors of the ovary: results from the MITO-9 study. Gynecol Oncol 2019;154:323327.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 99.

    Wang D, Cao D, Jia C, . Analysis of oncologic and reproductive outcomes after fertility-sparing surgery in apparent stage I adult ovarian granulosa cell tumors. Gynecol Oncol 2018;151:275281.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 100.

    Boyraz G, Durmus Y, Cicin I, . Prognostic factors and oncological outcomes of ovarian yolk sac tumors: a retrospective multicentric analysis of 99 cases. Arch Gynecol Obstet 2019;300:175182.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Hu T, Fang Y, Sun Q, . Clinical management of malignant ovarian germ cell tumors: a 26-year experience in a tertiary care institution. Surg Oncol 2019;31:813.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 102.

    Yang ZJ, Liu ZC, Wei RJ, . An analysis of prognostic factors in patients with ovarian malignant germ cell tumors who are treated with fertility-preserving surgery. Gynecol Obstet Invest 2016;81:19.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Nasioudis D, Mastroyannis SA, Latif NA, . Trends in the surgical management of malignant ovarian germcell tumors. Gynecol Oncol 2020;157:8993.

  • 104.

    Yang ZJ, Wei RJ, Li L. [Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery]. Zhonghua Fu Chan Ke Za Zhi 2012;47:898904.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Chan JK, Tewari KS, Waller S, . The influence of conservative surgical practices for malignant ovarian germ cell tumors. J Surg Oncol 2008;98:111116.

  • 106.

    Schlaerth AC, Chi DS, Poynor EA, . Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. Int J Gynecol Cancer 2009;19:11991204.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Schilder JM, Thompson AM, DePriest PD, . Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 2002;87:17.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108.

    Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol 2007;25:28732883.

  • 109.

    Wright JD, Shah M, Mathew L, . Fertility preservation in young women with epithelial ovarian cancer. Cancer 2009;115:41184126.

  • 110.

    Satoh T, Hatae M, Watanabe Y, . Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol 2010;28:17271732.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 111.

    Gershenson DM. Treatment of ovarian cancer in young women. Clin Obstet Gynecol 2012;55:6574.

  • 112.

    Stier EA, Barakat RR, Curtin JP, . Laparotomy to complete staging of presumed early ovarian cancer. Obstet Gynecol 1996;87:737740.

  • 113.

    Soper JT, Johnson P, Johnson V, . Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma. Obstet Gynecol 1992;80:949953.

  • 114.

    Schreuder HW, Pattij TO, Zweemer RP, . Increasing experience in laparoscopic staging of early ovarian cancer. Gynecol Surg 2012;9:8996.

  • 115.

    Hengeveld EM, Zusterzeel PLM, Lajer H, . The value of surgical staging in patients with apparent early stage epithelial ovarian carcinoma. Gynecol Oncol 2019;154:308313.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Babayeva A, Braicu EI, Grabowski JP, . Clinical outcome after completion surgery in patients with ovarian cancer: the charite experience. Int J Gynecol Cancer 2018;28:14911497.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    Billmire D, Vinocur C, Rescorla F, . Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg 2004;39:424429, discussion 424–429.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 118.

    Mangili G, Sigismondi C, Lorusso D, . The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study. Ann Oncol 2017;28:333338.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 119.

    Park JY, Kim DY, Suh DS, . Significance of the complete surgical staging of stage I malignant ovarian germ cell tumors. Ann Surg Oncol 2016;23:29822987.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 120.

    Wang D, Zhu S, Jia C, . Role of staging surgery and adjuvant chemotherapy in adult patients with apparent stage I pure immature ovarian teratoma after fertility-sparing surgery. Int J Gynecol Cancer 2020;30:664669.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 121.

    Bristow RE, Tomacruz RS, Armstrong DK, . Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:12481259.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 122.

    Eisenhauer EL, Abu-Rustum NR, Sonoda Y, . The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 2006;103:10831090.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 123.

    du Bois A, Reuss A, Pujade-Lauraine E, . Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 2009;115:12341244.

    • Search Google Scholar
    • Export Citation
  • 124.

    Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining ‘optimal’ residual disease. Gynecol Oncol 2012;125:483492.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 125.

    Elattar A, Bryant A, Winter-Roach BA, . Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2011;8:CD007565.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 126.

    Schorge JO, Garrett LA, Goodman A. Cytoreductive surgery for advanced ovarian cancer: quo vadis? Oncology (Williston Park) 2011;25:928934.

    • Search Google Scholar
    • Export Citation
  • 127.

    Chi DS, Eisenhauer EL, Zivanovic O, . Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009;114:2631.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 128.

    Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009;112:265274.

  • 129.

    Aletti GD, Dowdy SC, Gostout BS, . Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006;107:7785.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Eisenhauer EL, Abu-Rustum NR, Sonoda Y, . The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 2008;108:276281.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 131.

    Vergote I, De Brabanter J, Fyles A, . Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357:176182.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 132.

    Eeles RA, Morden JP, Gore M, . Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial. J Clin Oncol 2015;33:41384144.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 133.

    The American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 126: Management of gynecologic issues in women with breast cancer. Obstet Gynecol 2012;119:666682.

    • Search Google Scholar
    • Export Citation
  • 134.

    Barton DL, Loprinzi C, Gostout B. Current management of menopausal symptoms in cancer patients. Oncology (Williston Park) 2002;16:6772, 74; discussion 75–76, 79–80.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 135.

    Jenkins MR, Sikon AL. Update on nonhormonal approaches to menopausal management. Cleve Clin J Med 2008;75(Suppl 4):S17S24.

  • 136.

    Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer 1999;86:10131018.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 137.

    Eeles RA, Tan S, Wiltshaw E, . Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991;302:259262.

  • 138.

    Maggioni A, Benedetti Panici P, Dell’Anna T, . Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 2006;95:699704.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 139.

    Chiyoda T, Sakurai M, Satoh T, . Lymphadenectomy for primary ovarian cancer: a systematic review and meta-analysis. J Gynecol Oncol 2020;31:e67.

  • 140.

    Gu HF, Zhou Y, Li YX, . [Prognostic significance of systematic retroperitoneal lymphadenectomy in patients with epithelial ovarian cancer: a Meta-analysis]. Zhonghua Yi Xue Za Zhi 2016;96:30203025.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 141.

    Ditto A, Martinelli F, Reato C, . Systematic para-aortic and pelvic lymphadenectomy in early stage epithelial ovarian cancer: a prospective study. Ann Surg Oncol 2012;19:38493855.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 142.

    Svolgaard O, Lidegaard O, Nielsen ML, . Lymphadenectomy in surgical stage I epithelial ovarian cancer. Acta Obstet Gynecol Scand 2014;93:256260.

  • 143.

    Oshita T, Itamochi H, Nishimura R, . Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group. Int J Clin Oncol 2013;18:11071113.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 144.

    Lago V, Minig L, Fotopoulou C. Incidence of lymph node metastases in apparent early-stage low-grade epithelial ovarian cancer: a comprehensive review. Int J Gynecol Cancer 2016;26:14071414.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 145.

    Desteli GA, Gultekin M, Usubutun A, . Lymph node metastasis in grossly apparent clinical stage Ia epithelial ovarian cancer: Hacettepe experience and review of literature. World J Surg Oncol 2010;8:106.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 146.

    Scarabelli C, Gallo A, Zarrelli A, . Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival. Gynecol Oncol 1995;56:328337.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 147.

    Scarabelli C, Gallo A, Visentin MC, . Systematic pelvic and para-aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal disease. Int J Gynecol Cancer 1997;7:1826.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 148.

    Panici PB, Maggioni A, Hacker N, . Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005;97:560566.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 149.

    Dell’ Anna T, Signorelli M, Benedetti-Panici P, . Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial. Br J Cancer 2012;107:785792.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 150.

    Harter P, Sehouli J, Lorusso D, . A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 2019;380:822832.

  • 151.

    du Bois A, Reuss A, Harter P, . Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol 2010;28:17331739.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 152.

    Kim HS, Ju W, Jee BC, . Systematic lymphadenectomy for survival in epithelial ovarian cancer: a meta-analysis. Int J Gynecol Cancer 2010;20:520528.

  • 153.

    Zhou J, Shan G, Chen Y. The effect of lymphadenectomy on survival and recurrence in patients with ovarian cancer: a systematic review and meta-analysis. Jpn J Clin Oncol 2016;46:718726.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 154.

    Whitney CW, Spirtos N. Gynecologic Oncology Group surgical procedures manual. Gynecologic Oncology Group, Philadelphia. 2010.

  • 155.

    Aletti GD, Powless C, Bakkum-Gamez J, . Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy. Gynecol Oncol 2009;114:3236.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 156.

    Wimberger P, Lehmann N, Kimmig R, . Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2007;106:6974.

    • Search Google Scholar
    • Export Citation
  • 157.

    Gourley C, Walker JL, Mackay HJ. Update on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer. Am Soc Clin Oncol Educ Book 2016;35:143151.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 158.

    Armstrong DK, Bundy B, Wenzel L, . Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:3443.

  • 159.

    Young RC, Walton LA, Ellenberg SS, . Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990;322:10211027.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 160.

    Winter-Roach BA, Kitchener HC, Dickinson HO. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev 2009;CD004706.

    • Search Google Scholar
    • Export Citation
  • 161.

    Högberg T, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 2001;40:340360.

  • 162.

    Bolis G, Colombo N, Pecorelli S, . Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol 1995;6:887893.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 163.

    Trimbos JB, Parmar M, Vergote I, . International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95:105112.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 164.

    Trimbos JB, Vergote I, Bolis G, . Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003;95:113125.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 165.

    Tropé C, Kaern J, Hogberg T, . Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol 2000;11:281288.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 166.

    Moore K, Colombo N, Scambia G, . Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379:24952505.

  • 167.

    Ray-Coquard I, Pautier P, Pignata S, . Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019;381:24162428.

  • 168.

    González-Martín A, Pothuri B, Vergote I, . Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381:23912402.

  • 169.

    Coleman RL, Fleming GF, Brady MF, . Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 2019;381:24032415.

  • 170.

    Fehr MK, Welter J, Sell W, . Sensor-controlled scalp cooling to prevent chemotherapy-induced alopecia in female cancer patients. Curr Oncol 2016;23:e576e582.

  • 171.

    Pignata S, Scambia G, Katsaros D, . Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2014;15:396405.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 172.

    Clamp AR, James EC, McNeish IA, . Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet 2019;394:20842095.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 173.

    Blagden SP, Cook AD, Poole C, . Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncol 2020;21:969977.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 174.

    Katsumata N, Yasuda M, Takahashi F, . Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:13311338.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 175.

    Katsumata N, Yasuda M, Isonishi S, . Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013;14:10201026.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 176.

    Harano K, Terauchi F, Katsumata N, . Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Ann Oncol 2014;25:251257.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 177.

    Chan JK, Brady MF, Penson RT, . Weekly vs every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med 2016;374:738748.

  • 178.

    Pignata S, Scambia G, Ferrandina G, . Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol 2011;29:36283635.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 179.

    Vasey PA, Jayson GC, Gordon A, . Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:16821691.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 180.

    Neijt JP, Engelholm SA, Witteveen PO, . Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis. Semin Oncol 1997;24:S15S39.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 181.

    Neijt JP, Engelholm SA, Tuxen MK, . Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:30843092.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 182.

    Ozols RF, Bundy BN, Greer BE, . Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:31943200.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 183.

    du Bois A, Lück HJ, Meier W, . A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:13201329.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 184.

    Greimel ER, Bjelic-Radisic V, Pfisterer J, . Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol 2006;24:579586.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 185.

    Hilpert F, du Bois A, Greimel ER, . Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany. Ann Oncol 2007;18:282287.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 186.

    Li L, Zhuang Q, Cao Z, . Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial. Oncol Lett 2018;15:36463652.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 187.

    International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505515.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 188.

    Aravantinos G, Fountzilas G, Kosmidis P, . Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. Ann Oncol 2005;16:11161122.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 189.

    du Bois A, Weber B, Rochon J, . Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. J Clin Oncol 2006;24:11271135.

    • Search Google Scholar
    • Export Citation
  • 190.

    Pfisterer J, Weber B, Reuss A, .GINECO. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006;98:10361045.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 191.

    Bookman MA, Brady MF, McGuire WP, . Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009;27:14191425.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 192.

    Olawaiye AB, Java JJ, Krivak TC, . Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2018;151:1823.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 193.

    Bolis G, Scarfone G, Raspagliesi F, . Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study. Eur J Cancer 2010;46:29052912.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 194.

    du Bois A, Herrstedt J, Hardy-Bessard AC, . Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 2010;28:41624169.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 195.

    Hoskins P, Vergote I, Cervantes A, . Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst 2010;102:15471556.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 196.

    Lindemann K, Christensen RD, Vergote I, . First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. Ann Oncol 2012;23:26132619.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 197.

    Wadler S, Yeap B, Vogl S, . Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. Cancer 1996;77:733742.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 198.

    Muggia FM, Braly PS, Brady MF, . Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000;18:106115.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 199.

    Alberts DS, Green S, Hannigan EV, . Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992;10:706717.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 200.

    Hannigan EV, Green S, Alberts DS, . Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. Oncology 1993;50(Suppl 2):29.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 201.

    Swenerton K, Jeffrey J, Stuart G, . Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992;10:718726.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 202.

    Taylor AE, Wiltshaw E, Gore ME, . Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 1994;12:20662070.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 203.

    Meerpohl HG, Sauerbrei W, Kühnle H, . Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. Gynecol Oncol 1997;66:7584.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 204.

    Skarlos DV, Aravantinos G, Kosmidis P, . Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study. Semin Oncol 1997;24 (Suppl 15):5761.

    • Search Google Scholar
    • Export Citation
  • 205.

    McGuire WP, Hoskins WJ, Brady MF, . Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:16.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 206.

    Piccart MJ, Bertelsen K, James K, . Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699708.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 207.

    Piccart MJ, Bertelsen K, Stuart G, . Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 2003;13(Suppl 2):144148.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 208.

    Skarlos DV, Aravantinos G, Kosmidis P, . Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study. Eur J Cancer 1996;32A:421428.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 209.

    ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. Lancet 1998;352:15711576.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 210.

    Wils J, van Geuns H, Stoot J, . Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg. Anticancer Drugs 1999;10:257261.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 211.

    Möbus V, Wandt H, Frickhofen N, . Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol 2007;25:41874193.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 212.

    Hershman DL, Till C, Wright JD, . Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group Clinical Trials. J Clin Oncol 2016;34:30143022.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 213.

    Spriggs DR, Brady MF, Vaccarello L, . Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:44664471.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 214.

    Banerjee S, Rustin G, Paul J, . A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Ann Oncol 2013;24:679687.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 215.

    Bell J, Brady MF, Young RC, . Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006;102:432439.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 216.

    Chan JK, Tian C, Fleming GF, . The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol 2010;116:301306.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 217.

    Hakes TB, Chalas E, Hoskins WJ, . Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992;45:284289.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 218.

    Lambert HE, Rustin GJ, Gregory WM, . A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol 1997;8:327333.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 219.

    Burger RA, Brady MF, Bookman MA, . Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:24732483.

  • 220.

    Perren TJ, Swart AM, Pfisterer J, . A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:24842496.

  • 221.